Chinese General Practice ›› 2023, Vol. 26 ›› Issue (14): 1758-1765.DOI: 10.12114/j.issn.1007-9572.2022.0798
• Original Research • Previous Articles Next Articles
Received:
2022-08-10
Revised:
2022-12-15
Published:
2023-05-15
Online:
2023-01-18
Contact:
GUO Zhiguo
通讯作者:
郭治国
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0798
序号 | 性别 | 年龄(岁) | 既往史 | ||||||
---|---|---|---|---|---|---|---|---|---|
精神疾病 | 高血压 | 糖尿病 | 冠心病 | 陈旧脑梗死 | 肾病综合征 | 缺铁性贫血 | |||
1 | 男 | 29 | + | - | - | - | - | - | - |
2 | 女 | 26 | - | - | - | - | - | - | - |
3 | 男 | 39 | - | + | + | - | - | - | - |
4 | 男 | 56 | + | + | - | - | - | - | - |
5 | 男 | 64 | + | + | + | + | + | - | - |
6 | 男 | 74 | - | + | + | - | + | - | - |
7 | 男 | 39 | - | + | - | - | - | - | - |
8 | 女 | 26 | - | - | - | - | - | - | - |
9 | 男 | 23 | - | - | - | - | - | + | - |
10 | 女 | 43 | + | + | - | - | - | - | + |
11 | 男 | 19 | + | - | - | - | - | - | - |
Table 1 Demographic characteristics of patients
序号 | 性别 | 年龄(岁) | 既往史 | ||||||
---|---|---|---|---|---|---|---|---|---|
精神疾病 | 高血压 | 糖尿病 | 冠心病 | 陈旧脑梗死 | 肾病综合征 | 缺铁性贫血 | |||
1 | 男 | 29 | + | - | - | - | - | - | - |
2 | 女 | 26 | - | - | - | - | - | - | - |
3 | 男 | 39 | - | + | + | - | - | - | - |
4 | 男 | 56 | + | + | - | - | - | - | - |
5 | 男 | 64 | + | + | + | + | + | - | - |
6 | 男 | 74 | - | + | + | - | + | - | - |
7 | 男 | 39 | - | + | - | - | - | - | - |
8 | 女 | 26 | - | - | - | - | - | - | - |
9 | 男 | 23 | - | - | - | - | - | + | - |
10 | 女 | 43 | + | + | - | - | - | - | + |
11 | 男 | 19 | + | - | - | - | - | - | - |
序号 | 服药类型 | 服药剂量 | 同服药物或物质 | 过量服药至就诊间隔时间(h) | 超量药物血药浓度 |
---|---|---|---|---|---|
1 | 自服 | 苯磺酸左氨氯地平(2.5 mg)700片 | 无 | 9.33 | 氨氯地平890 μg/L |
2 | 自服 | 苯磺酸左氨氯地平(2.5 mg)35片,缬沙坦氨氯地平(80 mg/5 mg)28片 | 盐酸地芬尼多(25 mg)30片,卡托普利(12.5 mg)30~40片,茶苯海明(25 mg)20片,白酒250 ml | 6.5 | 氨氯地平219.7 μg/L,缬沙坦43.7 mg/L,地芬尼多3.1 mg/L,苯海拉明2.7 mg/L,卡托普利0.5 mg/L |
3 | 处方剂量 | 氨氯地平阿托伐他汀(5 mg/20 mg)共4片 | 氯沙坦氢氯噻嗪(50 mg/12.5 mg)4片,阿罗洛尔(10 mg)2片,红酒150 ml | 不能明确 | 氨氯地平26.9 μg/L,氯沙坦23.6 μg/L,阿托伐他汀32.5 μg/L,阿罗洛尔33.5 μg/L,乙醇146.6 mg/L |
4 | 自服 | 苯磺酸氨氯地平(5 mg)4片,苯磺酸左氨氯地平(2.5 mg)2片 | 奥美沙坦(20 mg)2片 | 1 | 氨氯地平35.7 μg/L |
5 | 自服 | 苯磺酸左氨氯地平(具体剂型不详)24片 | 佐匹克隆,剂型剂量不详 | 7 | 氨氯地平61 μg/L,佐匹克隆0.6 mg/L,美托洛尔1.2 mg/L |
6 | 误服 | 硝苯地平控释片(30 mg)7片 | 无 | 1 | 硝苯地平0.2 mg/L |
7 | 自服 | 硝苯地平控释片(具体剂型不详)100片,非洛地平(具体剂型不详)100片,马来酸左旋氨氯地平(具体剂型不详)20片 | 阿卡波糖(具体剂型不详)100片 | 10 | 氨氯地平39 μg/L,奥美沙坦0.8 mg/L,比索洛尔0.2 mg/L,二甲双胍5.4 mg/L |
8 | 自服 | 贝尼地平(8 mg)80片 | 无 | 0.5 | 贝尼地平108 μg/L |
9 | 自服 | 硝苯地平缓释片(20 mg)60片,苯磺酸氨氯地平(5 mg)10片 | 地高辛(0.25 mg)100片,卡托普利(12.5 mg)200片 | 3 | 硝苯地平1.1 mg/L,地高辛74 μg/L,卡托普利1.4 mg/L |
10 | 自服 | 维拉帕米(具体剂型不详)100片 | 美托洛尔(具体剂型不详)200片 | 1.5 | 维拉帕米1.5 mg/L,美托洛尔1.25 mg/L |
11 | 自服 | 硝苯地平(10 mg)200片 | 艾司唑仑(具体剂型不详),唑吡坦(具体剂型不详)共20余片,皮下注射门冬胰岛素约180 U | 1 | 硝苯地平4.8 mg/L,唑吡坦1.3 mg/L,艾司唑仑0.3 mg/L |
Table 2 The oral dose and maximum plasma concentration of calcium channel blockers in patients
序号 | 服药类型 | 服药剂量 | 同服药物或物质 | 过量服药至就诊间隔时间(h) | 超量药物血药浓度 |
---|---|---|---|---|---|
1 | 自服 | 苯磺酸左氨氯地平(2.5 mg)700片 | 无 | 9.33 | 氨氯地平890 μg/L |
2 | 自服 | 苯磺酸左氨氯地平(2.5 mg)35片,缬沙坦氨氯地平(80 mg/5 mg)28片 | 盐酸地芬尼多(25 mg)30片,卡托普利(12.5 mg)30~40片,茶苯海明(25 mg)20片,白酒250 ml | 6.5 | 氨氯地平219.7 μg/L,缬沙坦43.7 mg/L,地芬尼多3.1 mg/L,苯海拉明2.7 mg/L,卡托普利0.5 mg/L |
3 | 处方剂量 | 氨氯地平阿托伐他汀(5 mg/20 mg)共4片 | 氯沙坦氢氯噻嗪(50 mg/12.5 mg)4片,阿罗洛尔(10 mg)2片,红酒150 ml | 不能明确 | 氨氯地平26.9 μg/L,氯沙坦23.6 μg/L,阿托伐他汀32.5 μg/L,阿罗洛尔33.5 μg/L,乙醇146.6 mg/L |
4 | 自服 | 苯磺酸氨氯地平(5 mg)4片,苯磺酸左氨氯地平(2.5 mg)2片 | 奥美沙坦(20 mg)2片 | 1 | 氨氯地平35.7 μg/L |
5 | 自服 | 苯磺酸左氨氯地平(具体剂型不详)24片 | 佐匹克隆,剂型剂量不详 | 7 | 氨氯地平61 μg/L,佐匹克隆0.6 mg/L,美托洛尔1.2 mg/L |
6 | 误服 | 硝苯地平控释片(30 mg)7片 | 无 | 1 | 硝苯地平0.2 mg/L |
7 | 自服 | 硝苯地平控释片(具体剂型不详)100片,非洛地平(具体剂型不详)100片,马来酸左旋氨氯地平(具体剂型不详)20片 | 阿卡波糖(具体剂型不详)100片 | 10 | 氨氯地平39 μg/L,奥美沙坦0.8 mg/L,比索洛尔0.2 mg/L,二甲双胍5.4 mg/L |
8 | 自服 | 贝尼地平(8 mg)80片 | 无 | 0.5 | 贝尼地平108 μg/L |
9 | 自服 | 硝苯地平缓释片(20 mg)60片,苯磺酸氨氯地平(5 mg)10片 | 地高辛(0.25 mg)100片,卡托普利(12.5 mg)200片 | 3 | 硝苯地平1.1 mg/L,地高辛74 μg/L,卡托普利1.4 mg/L |
10 | 自服 | 维拉帕米(具体剂型不详)100片 | 美托洛尔(具体剂型不详)200片 | 1.5 | 维拉帕米1.5 mg/L,美托洛尔1.25 mg/L |
11 | 自服 | 硝苯地平(10 mg)200片 | 艾司唑仑(具体剂型不详),唑吡坦(具体剂型不详)共20余片,皮下注射门冬胰岛素约180 U | 1 | 硝苯地平4.8 mg/L,唑吡坦1.3 mg/L,艾司唑仑0.3 mg/L |
序号 | 临床表现 | |||||||
---|---|---|---|---|---|---|---|---|
休克 | 恶心呕吐 | 头晕 | 乏力 | 心率增快 | 心率减慢 | 晕厥 | 昏睡 | |
1 | + | - | - | - | + | - | - | - |
2 | + | + | + | + | - | - | - | - |
3 | + | - | + | - | - | - | + | - |
4 | - | - | - | - | - | - | - | - |
5 | + | - | - | + | - | - | - | - |
6 | - | - | - | - | - | - | - | - |
7 | + | + | + | + | - | + | - | - |
8 | + | + | - | - | + | - | - | - |
9 | + | + | + | - | - | - | - | - |
10 | + | + | - | - | - | + | - | + |
11 | + | - | - | - | + | - | - | - |
Table 3 Clinical manifestations of patients on arrival
序号 | 临床表现 | |||||||
---|---|---|---|---|---|---|---|---|
休克 | 恶心呕吐 | 头晕 | 乏力 | 心率增快 | 心率减慢 | 晕厥 | 昏睡 | |
1 | + | - | - | - | + | - | - | - |
2 | + | + | + | + | - | - | - | - |
3 | + | - | + | - | - | - | + | - |
4 | - | - | - | - | - | - | - | - |
5 | + | - | - | + | - | - | - | - |
6 | - | - | - | - | - | - | - | - |
7 | + | + | + | + | - | + | - | - |
8 | + | + | - | - | + | - | - | - |
9 | + | + | + | - | - | - | - | - |
10 | + | + | - | - | - | + | - | + |
11 | + | - | - | - | + | - | - | - |
序号 | 白细胞计数升高 | 乳酸升高 | 高血糖 | 急性肾功能不全 | 代谢性酸中毒 | 肌钙蛋白I升高 |
---|---|---|---|---|---|---|
1 | + | + | + | + | + | - |
2 | + | + | - | - | - | - |
3 | + | + | + | - | - | - |
4 | + | + | - | - | - | - |
5 | + | - | + | - | - | - |
6 | - | - | - | - | - | - |
7 | + | + | - | + | + | - |
8 | - | + | + | - | - | - |
9 | + | - | - | + | - | + |
10 | - | + | + | - | - | + |
11 | + | + | - | - | - | - |
Table 4 The abnormal results of patient's first laboratory test
序号 | 白细胞计数升高 | 乳酸升高 | 高血糖 | 急性肾功能不全 | 代谢性酸中毒 | 肌钙蛋白I升高 |
---|---|---|---|---|---|---|
1 | + | + | + | + | + | - |
2 | + | + | - | - | - | - |
3 | + | + | + | - | - | - |
4 | + | + | - | - | - | - |
5 | + | - | + | - | - | - |
6 | - | - | - | - | - | - |
7 | + | + | - | + | + | - |
8 | - | + | + | - | - | - |
9 | + | - | - | + | - | + |
10 | - | + | + | - | - | + |
11 | + | + | - | - | - | - |
化验 | 1号 | 7号 | 9号 | 10号 | |
---|---|---|---|---|---|
白细胞计数(×109/L) | 来诊 | 29.90 | 19.31 | 17.19 | 8.90 |
最差 | 29.90 | 19.31 | 35.49 | 30.14 | |
血小板计数(×109/L) | 来诊 | 199 | 485 | 539 | 333 |
最差 | 48 | 63 | 103 | 85 | |
肌酐(μmol/L) | 来诊 | 251 | 426 | 158 | 83 |
最差 | 364 | 426 | 259 | 233 | |
丙氨酸氨基转移酶(U/L) | 来诊 | 25 | 24 | 10 | 67 |
最差 | 250 | 5 350 | 323 | 71 | |
天冬氨酸氨基转移酶(U/L) | 来诊 | 33 | 28 | 23 | 61 |
最差 | 850 | 10 480 | 548 | 110 | |
总胆红素(μmol/L) | 来诊 | 8.8 | 9.4 | 15.5 | 10.4 |
最差 | 22.4 | 87.9 | 46.8 | 44.2 | |
肌钙蛋白I(μg/L) | 来诊 | <0.010 | <0.010 | 3.200 | 0.024 |
最差 | 3.200 | 12.000 | 19.000 | 0.032 | |
肌酸激酶(U/L) | 来诊 | 43 | 55 | 167 | 34 |
最差 | >16 000 | 13 934 | 24 101 | 2 242 | |
葡萄糖(mmol/L) | 来诊 | 15.4 | 5.6 | 8.1 | 24.0 |
最差 | 36.1 | 34.3 | 19.5 | 24.0 | |
pH值 | 来诊 | 7.32 | 7.05 | 7.53 | 7.48 |
最差 | 7.06 | 6.80 | 7.07 | 7.23 | |
脂肪酶(U/L) | 来诊 | 136 | 343 | 62 | 80 |
最差 | >2 000 | >2 000 | 929 | 431 | |
淀粉酶(U/L) | 来诊 | 89 | 70 | 135 | 57 |
最差 | 642 | 559 | 276 | 351 | |
凝血酶原时间(s) | 来诊 | 11.3 | 14.3 | 10.9 | 14.9 |
最差 | 12.9 | 未再测 | 15.0 | 15.4 | |
凝血酶原活动度(%) | 来诊 | 88 | 65 | 96 | 61 |
最差 | 67 | 未再测 | 51 | 59 | |
活化部分凝血活酶(s) | 来诊 | 26.6 | 31.6 | 34.5 | 100.7 |
最差 | 182.3 | 未再测 | 62.8 | 206.4 | |
纤维蛋白降解产物(mg/L) | 来诊 | <2.5 | <2.5 | <2.5 | 23.4 |
最差 | 6.1 | 未再测 | 42.1 | 33.4 | |
D二聚体(mg/L) | 来诊 | <0.15 | 0.21 | <0.15 | 3.62 |
最差 | 0.69 | 未再测 | 5.34 | 3.62 |
Table 5 Main laboratory results of patients with multiple organ dysfunction
化验 | 1号 | 7号 | 9号 | 10号 | |
---|---|---|---|---|---|
白细胞计数(×109/L) | 来诊 | 29.90 | 19.31 | 17.19 | 8.90 |
最差 | 29.90 | 19.31 | 35.49 | 30.14 | |
血小板计数(×109/L) | 来诊 | 199 | 485 | 539 | 333 |
最差 | 48 | 63 | 103 | 85 | |
肌酐(μmol/L) | 来诊 | 251 | 426 | 158 | 83 |
最差 | 364 | 426 | 259 | 233 | |
丙氨酸氨基转移酶(U/L) | 来诊 | 25 | 24 | 10 | 67 |
最差 | 250 | 5 350 | 323 | 71 | |
天冬氨酸氨基转移酶(U/L) | 来诊 | 33 | 28 | 23 | 61 |
最差 | 850 | 10 480 | 548 | 110 | |
总胆红素(μmol/L) | 来诊 | 8.8 | 9.4 | 15.5 | 10.4 |
最差 | 22.4 | 87.9 | 46.8 | 44.2 | |
肌钙蛋白I(μg/L) | 来诊 | <0.010 | <0.010 | 3.200 | 0.024 |
最差 | 3.200 | 12.000 | 19.000 | 0.032 | |
肌酸激酶(U/L) | 来诊 | 43 | 55 | 167 | 34 |
最差 | >16 000 | 13 934 | 24 101 | 2 242 | |
葡萄糖(mmol/L) | 来诊 | 15.4 | 5.6 | 8.1 | 24.0 |
最差 | 36.1 | 34.3 | 19.5 | 24.0 | |
pH值 | 来诊 | 7.32 | 7.05 | 7.53 | 7.48 |
最差 | 7.06 | 6.80 | 7.07 | 7.23 | |
脂肪酶(U/L) | 来诊 | 136 | 343 | 62 | 80 |
最差 | >2 000 | >2 000 | 929 | 431 | |
淀粉酶(U/L) | 来诊 | 89 | 70 | 135 | 57 |
最差 | 642 | 559 | 276 | 351 | |
凝血酶原时间(s) | 来诊 | 11.3 | 14.3 | 10.9 | 14.9 |
最差 | 12.9 | 未再测 | 15.0 | 15.4 | |
凝血酶原活动度(%) | 来诊 | 88 | 65 | 96 | 61 |
最差 | 67 | 未再测 | 51 | 59 | |
活化部分凝血活酶(s) | 来诊 | 26.6 | 31.6 | 34.5 | 100.7 |
最差 | 182.3 | 未再测 | 62.8 | 206.4 | |
纤维蛋白降解产物(mg/L) | 来诊 | <2.5 | <2.5 | <2.5 | 23.4 |
最差 | 6.1 | 未再测 | 42.1 | 33.4 | |
D二聚体(mg/L) | 来诊 | <0.15 | 0.21 | <0.15 | 3.62 |
最差 | 0.69 | 未再测 | 5.34 | 3.62 |
序号 | 洗胃 | 活性炭 | 导泻 | 补液 | 升压药 | 钙剂 | 高剂量胰岛素 | 脂肪乳 | 阿托品 | 临时起搏 | 心肺复苏 | 气管插管 | ECMO | 血液净化 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | +a | - | - | + | + | + | + | + | - | - | + | + | + | + |
2 | + | + | - | + | + | + | + | + | - | - | - | - | - | + |
3 | - | - | - | + | - | - | - | - | - | - | - | - | - | - |
4 | + | - | - | + | - | - | - | - | - | - | - | - | - | - |
5 | +a | - | - | + | + | + | + | - | - | - | - | - | - | - |
6 | + | - | - | + | - | - | - | - | - | - | - | - | - | - |
7 | + | + | + | + | + | + | + | + | + | - | + | + | + | + |
8 | + | - | - | + | + | + | + | + | - | - | - | - | - | - |
9 | + | - | - | + | + | + | + | - | - | - | + | + | + | + |
10 | + | + | + | + | + | + | + | + | + | + | - | + | + | + |
11 | + | - | - | + | + | + | + | + | - | - | - | + | - | + |
Table 6 Therapeutic measures for patients
序号 | 洗胃 | 活性炭 | 导泻 | 补液 | 升压药 | 钙剂 | 高剂量胰岛素 | 脂肪乳 | 阿托品 | 临时起搏 | 心肺复苏 | 气管插管 | ECMO | 血液净化 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | +a | - | - | + | + | + | + | + | - | - | + | + | + | + |
2 | + | + | - | + | + | + | + | + | - | - | - | - | - | + |
3 | - | - | - | + | - | - | - | - | - | - | - | - | - | - |
4 | + | - | - | + | - | - | - | - | - | - | - | - | - | - |
5 | +a | - | - | + | + | + | + | - | - | - | - | - | - | - |
6 | + | - | - | + | - | - | - | - | - | - | - | - | - | - |
7 | + | + | + | + | + | + | + | + | + | - | + | + | + | + |
8 | + | - | - | + | + | + | + | + | - | - | - | - | - | - |
9 | + | - | - | + | + | + | + | - | - | - | + | + | + | + |
10 | + | + | + | + | + | + | + | + | + | + | - | + | + | + |
11 | + | - | - | + | + | + | + | + | - | - | - | + | - | + |
序号 | 血液灌流 | CVVH | 血液灌流+CVVH | 血浆置换 |
---|---|---|---|---|
1 | 1 | 2 | 2 | 3 |
2 | 7 | — | — | — |
7 | 2 | 3 | 2 | — |
9 | 3 | 6 | — | — |
10 | 6 | 8 | — | 1 |
11 | 3 | — | — | — |
Table 7 Methods and times of blood purification
序号 | 血液灌流 | CVVH | 血液灌流+CVVH | 血浆置换 |
---|---|---|---|---|
1 | 1 | 2 | 2 | 3 |
2 | 7 | — | — | — |
7 | 2 | 3 | 2 | — |
9 | 3 | 6 | — | — |
10 | 6 | 8 | — | 1 |
11 | 3 | — | — | — |
序号 | 血液灌流前 | 血液灌流后 | 下降比例(%) | 血浆置换前 | 血浆置换后 | 下降比例(%) |
---|---|---|---|---|---|---|
1 | 氨氯地平890 μg/L | 氨氯地平785 μg/L | 11.80 | 氨氯地平785 μg/L | 氨氯地平658 μg/L | 16.18 |
2 | 氨氯地平219.7 μg/L | 氨氯地平198.9 μg/L | 9.47 | — | — | — |
7 | 氨氯地平39 μg/L;硝苯地平0.10 mg/L | 氨氯地平31 μg/L;硝苯地平0.06 mg/L | 20.51;40.00 | — | — | — |
9 | 硝苯地平1.1 mg/L | 硝苯地平0.4 mg/L | 63.64 | — | — | — |
10 | 维拉帕米1.5 mg/L | 维拉帕米1.1 mg/L | 26.67 | 维拉帕米1.1 mg/L | 维拉帕米1.0 mg/L | 9.09 |
11 | 硝苯地平4.8 mg/L | 硝苯地平1.8 mg/L | 62.50 | — | — | — |
Table 8 The plasma concentration of patients before and after the first blood purification
序号 | 血液灌流前 | 血液灌流后 | 下降比例(%) | 血浆置换前 | 血浆置换后 | 下降比例(%) |
---|---|---|---|---|---|---|
1 | 氨氯地平890 μg/L | 氨氯地平785 μg/L | 11.80 | 氨氯地平785 μg/L | 氨氯地平658 μg/L | 16.18 |
2 | 氨氯地平219.7 μg/L | 氨氯地平198.9 μg/L | 9.47 | — | — | — |
7 | 氨氯地平39 μg/L;硝苯地平0.10 mg/L | 氨氯地平31 μg/L;硝苯地平0.06 mg/L | 20.51;40.00 | — | — | — |
9 | 硝苯地平1.1 mg/L | 硝苯地平0.4 mg/L | 63.64 | — | — | — |
10 | 维拉帕米1.5 mg/L | 维拉帕米1.1 mg/L | 26.67 | 维拉帕米1.1 mg/L | 维拉帕米1.0 mg/L | 9.09 |
11 | 硝苯地平4.8 mg/L | 硝苯地平1.8 mg/L | 62.50 | — | — | — |
序号 | 入院24 h APACHE Ⅱ评分(分) | 入院PSS评分(分) | 出院PSS评分(分) | 入院GCS评分(分) | 出院GCS评分(分) | 住院天数(d) | 出院时是否存活 | 入院到血流动力学稳定时间(h) |
---|---|---|---|---|---|---|---|---|
1 | 27 | 3 | 4 | 15 | — | 4 | 死亡 | — |
2 | 8 | 3 | 3 | 15 | 15 | 6 | 存活 | 92 |
3 | 5 | 2 | 2 | 15 | 15 | 1 | 存活 | 1 |
4 | 5 | 1 | 1 | 15 | 15 | 1 | 存活 | — |
5 | 9 | 3 | 3 | 15 | 15 | 7 | 存活 | 5 |
6 | 10 | 1 | 1 | 15 | 15 | 3 | 存活 | — |
7 | 43 | 3 | 4 | 15 | — | 3 | 死亡 | — |
8 | 7 | 3 | 3 | 15 | 15 | 4 | 存活 | 47 |
9 | 37 | 3 | 3 | 15 | 15 | 32 | 存活 | 50 |
10 | 32 | 3 | 3 | 9 | 15 | 20 | 存活 | 117 |
11 | 18 | 3 | 3 | 15 | 15 | 4 | 存活 | 97 |
Table 9 The clinical score at admission and discharge,hospitalization days and prognosis of patients
序号 | 入院24 h APACHE Ⅱ评分(分) | 入院PSS评分(分) | 出院PSS评分(分) | 入院GCS评分(分) | 出院GCS评分(分) | 住院天数(d) | 出院时是否存活 | 入院到血流动力学稳定时间(h) |
---|---|---|---|---|---|---|---|---|
1 | 27 | 3 | 4 | 15 | — | 4 | 死亡 | — |
2 | 8 | 3 | 3 | 15 | 15 | 6 | 存活 | 92 |
3 | 5 | 2 | 2 | 15 | 15 | 1 | 存活 | 1 |
4 | 5 | 1 | 1 | 15 | 15 | 1 | 存活 | — |
5 | 9 | 3 | 3 | 15 | 15 | 7 | 存活 | 5 |
6 | 10 | 1 | 1 | 15 | 15 | 3 | 存活 | — |
7 | 43 | 3 | 4 | 15 | — | 3 | 死亡 | — |
8 | 7 | 3 | 3 | 15 | 15 | 4 | 存活 | 47 |
9 | 37 | 3 | 3 | 15 | 15 | 32 | 存活 | 50 |
10 | 32 | 3 | 3 | 9 | 15 | 20 | 存活 | 117 |
11 | 18 | 3 | 3 | 15 | 15 | 4 | 存活 | 97 |
[1] |
|
[2] | |
[3] |
白京京,张伟丽,王璐,等. 北京市基层医疗卫生机构降压药物使用情况及合理性分析[J]. 中华心血管病杂志,2021,49(10):993-999. DOI:10.3760/cma.j.cn112148-20201231-01022.
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
心肺复苏后昏迷患者早期神经功能预后评估专家共识组. 心肺复苏后昏迷患者早期神经功能预后评估专家共识[J]. 中华急诊医学杂志,2019,28(2):156-162. DOI:10.3760/cma.j.issn.1671-0282.2019.02.006.
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
赵力,王晓冰,朱彦,等. 大鼠急性脑缺血-再灌注损伤及氨氯地平保护作用的研究[J]. 高血压杂志,1997,5(S1):23-26. DOI:10.16439/j.cnki.1673-7245.1997.s1.008.
|
[22] |
郭阳,张培东,谭盛. 左旋氨氯地平对局灶性脑缺血小鼠模型脑梗死体积的影响[J]. 今日药学,2014,24(1):4-6.
|
[23] |
|
[24] |
吴彼得,陈珊莹,许向农,等. 系列血液净化治疗急性重症中毒的疗效观察[J]. 中国全科医学,2011,14(20):2337-2339. DOI:10.3969/j.issn.1007-9572.2011.20.042.
|
[25] |
|
[26] |
何怀武,刘大为,柴文昭,等. 血浆置换抢救难治重症氨氯地平过量中毒一例[J]. 中华医学杂志,2010,90(5):359-360. DOI:10.3760/cma.j.issn.0376-2491.2010.05.019.
|
[27] |
|
[28] |
穆宇航,李星亮,逄利. 硝苯地平中毒致麻痹性肠梗阻一例[J]. 中华劳动卫生职业病杂志,2021,39(12):952-953. DOI:10.3760/cma.j.cn121094-20210129-00062.
|
[29] |
周榆然,胡系意,袁策,等. 不同评分系统对急性中毒预后评估价值的比较[J]. 中华劳动卫生职业病杂志,2018,36(11):808-812. DOI:10.3760/cma.j.issn.1001-9391.2018.11.002.
|
[30] |
|
[1] | HUANG Chuanying, LIAO Xiaoyang, YANG Rong, LI Dongze, ZHANG Peng, JIA Yu, LIU Lidi. Interpretation of the Clinical Statement for Management of Female Cardiac Emergencies in 2024 [J]. Chinese General Practice, 2025, 28(12): 1427-1432. |
[2] | Expert Group on the Consensus for Blood Purification Therapy Based on Pharmacokinetics in Acute Poisoning from Commonly Used Clinical Drugs. Consensus for Blood Purification Therapy Based on Pharmacokinetics in Acute Poisoning from Commonly Used Clinical Drugs [J]. Chinese General Practice, 2025, 28(09): 1033-1043. |
[3] | CUI Xiaona, FENG Ruixia, HAN Yupeng, ZHOU Yaoyao, LIU Xiaojun, LI Jianchao. A Comparative Study on Clinical Effects of Combined Auxiliary Sequence of VA-ECMO and IABP on Acute Myocardial Infarction Complicated with Cardiogenic Shock [J]. Chinese General Practice, 2023, 26(35): 4439-4445. |
[4] | MIAO Guangrui, PANG Shuo, ZHOU Yuanhang, DUAN Mingxuan, BAI Linpeng, ZHANG Qingyang, ZHAO Xiaoyan, DONG Jianzeng. Short-term Prognostic Value of Early Fluid Balance and Lactate Clearance in Patients with Acute Myocardial Infarction Combined with Cardiogenic Shock Treated with Extracorporeal Membrane Oxygenation [J]. Chinese General Practice, 2023, 26(27): 3397-3402. |
[5] | Expert group of expert consensus on the application of ulinastatin in common clinical critical illness. Expert Consensus on the Application of Ulinastatin in Common Clinical Critical Illness [J]. Chinese General Practice, 2023, 26(26): 3207-3219. |
[6] | DING Jing, MENG Zhuocheng, ZHANG Yan, CUI Xiaohua, LIU Jiarui, HE Jiao, ZHANG Yang, LI Yajuan, YANG Liu. Retrospective Analysis of 2 992 Times of Therapeutic Drug Monitoring of Valproic Acid from 2019 to 2021 [J]. Chinese General Practice, 2023, 26(23): 2923-2929. |
[7] | XU Wei, XU Jiyuan, LI Maoqin, LU Fei, CHENG Shuli. Predictive Value of Color Doppler Ultrasound for Acute Kidney Injury in Patients with Septic Shock [J]. Chinese General Practice, 2023, 26(09): 1104-1111. |
[8] | CHU Xiaoting, YANG Xiaoming, WAN Qiuping, ZHANG Guohui, XIONG Jianjing, FANG Jialie. Trend Analysis of Life Expectancy and Disease Spectrum in Residents of Jing'an District in Shanghai, 2016-2021 [J]. Chinese General Practice, 2022, 25(36): 4561-4566. |
[9] | Ziao RUI, Dongpu DAI, Yingying GUO, Shuo PANG, Yuanhang ZHOU, Yang DU, Xiaoyan ZHAO, Jianzeng DONG. Efficacy and Related Inflencing Factors of Intra-aortic Balloon Counterpulsation Combined with Extracorporeal Membrane Oxygenation in Patients with Acute Myocardial Infarction and Cardiogenic Shock [J]. Chinese General Practice, 2022, 25(21): 2597-2604. |
[10] |
GAN Junying, XU Heping, WU Kaifang, CHEN Yunmei, YE Xiaojuan.
Predictive Value of Age Shock Index for
Adverse Outcomes in Patients with Acute Gastrointestinal Bleeding
|
[11] |
FAN Guihong, HE Jun, PANG Gaofeng, LI Chen, JIANG Lushan, FANG Huimin, WANG Zhou.
Modified Electroconvulsive Therapy in Patients with Schizophrenia:Curative Effect and Responses of Neurotransmitters in Brain and Different Brain Regions [J]. Chinese General Practice, 2022, 25(03): 325-330. |
[12] | WANG Yueyue,XU Qixia. YEARS Algorithm:a New Diagnostic Strategy for Suspected Pulmonary Embolism [J]. Chinese General Practice, 2021, 24(26): 3383-3386. |
[13] | YU Jiangquan,ZHENG Ruiqiang,ZHU Jin,ZHAO Yuan,YANG Penglei. Velocity Time Integral Guides Fluid Therapy for COPD Patients with Septic Shock:a Clinical Study [J]. Chinese General Practice, 2021, 24(23): 2945-2949. |
[14] | ZHAO Hong,GE Hongxia,MA Qingbian,AN Yuping,GUO Zhiguo. Clinical Study of Characteristics of Acute Poisoning Caused by Difenidol Hydrochloride [J]. Chinese General Practice, 2021, 24(23): 2940-2944. |
[15] | XU Meixian,LIU Gang,CAO Lijing,SHI Xiaona,SUN Hui,LI June. The Main Early Clinical Features of Kawasaki Disease Shock Syndrome and Septic Shock in Children:a Comparative Study [J]. Chinese General Practice, 2020, 23(30): 3812-3816. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||